---
title: "CJC-1295 (no DAC) / Mod GRF(1-29)"
canonical_url: https://peptidelibrary.app/library/cjc-1295-no-dac
description: "Modified GRF(1-29), a growth hormone-releasing hormone analog carrying four amino-acid substitutions that resist enzymatic breakdown but without the drug affinity complex group that makes the DAC version long-acting. It is short-acting — its half-life is commonly estimated at about thirty minutes, although no published human study has measured it — rather than producing the multi-day elevation of DAC-CJC, and the two are pharmacologically distinct despite the shared name. Not FDA-approved. Prohibited in sport under WADA class S2."
updated: 2026-09-26
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# CJC-1295 (no DAC) / Mod GRF(1-29)

CJC-1295 (no DAC) / Mod GRF(1-29), also called Mod GRF 1-29 or CJC-1295 without DAC, is a short-acting GHRH analog in the Growth Hormone Secretagogue class. This is modified GRF(1-29), a GHRH analog carrying four amino-acid substitutions that protect it from dipeptidyl peptidase-4 cleavage but without the drug affinity complex group that lets the DAC version bind albumin.

Modified GRF(1-29), a growth hormone-releasing hormone analog carrying four amino-acid substitutions that resist enzymatic breakdown but without the drug affinity complex group that makes the DAC version long-acting. It is short-acting — its half-life is commonly estimated at about thirty minutes, although no published human study has measured it — rather than producing the multi-day elevation of DAC-CJC, and the two are pharmacologically distinct despite the shared name. Not FDA-approved. Prohibited in sport under WADA class S2.

Also known as: Mod GRF 1-29, CJC-1295 without DAC, Tetrasubstituted GRF.

Categories: Fat Loss, Muscle/Recovery, Experimental.

## Classification

- Type: Short-acting GHRH analog
- Mechanism class: Growth Hormone Secretagogue
- Development stage: Research only
- Regulatory class: Research compound, not FDA-approved

## Mechanism

This is modified GRF(1-29), a GHRH analog carrying four amino-acid substitutions that protect it from dipeptidyl peptidase-4 cleavage but without the drug affinity complex group that lets the DAC version bind albumin. It binds the pituitary GHRH receptor, raising cyclic AMP and stimulating growth hormone release, but its half-life remains short — commonly estimated at about thirty minutes rather than days, although no published human pharmacokinetic study has measured it. The practical consequence is a brief, discrete GH pulse resembling physiological release, in contrast to the sustained elevation produced by the DAC form. These are pharmacologically distinct compounds despite the shared name.

Targets: GHRH receptor.

Origin: Tetrasubstituted GHRH(1–29).

## Properties

- Molecular formula: C152H252N44O42
- Molecular weight: ≈3368 g/mol
- CAS number: 863288-34-0
- Half-life: Not measured in humans; commonly estimated at about 30 minutes (vs 6–8 days for the DAC form)

## Evidence

- Evidence level: Insufficient Evidence
- Highest documented: None documented
- Human trials: 0
- Controlled human trials: 0
- Preclinical sources: 0

No human dose is established for this compound.

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006. 2006. Human study (early or uncontrolled). Population: Healthy adults. Growth hormone and IGF-1 secretion. Research on a related compound, not this one. Limitations: Studied an analog, not CJC-1295 (no DAC) / Mod GRF(1-29) itself [Source](https://pubmed.ncbi.nlm.nih.gov/16352683/)
2. Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion. Acta Paediatr Suppl. 1993. 1993. Human study (early or uncontrolled). Population: Human subjects in a dose-response protocol. Growth hormone release and pharmacokinetics. Research on a related compound, not this one. Limitations: Studied an analog, not CJC-1295 (no DAC) / Mod GRF(1-29) itself [Source](https://pubmed.ncbi.nlm.nih.gov/8329825/)

## Safety

Side effects: Flushing; Transient GH-related edema.

Risks: WADA S2 prohibited; Often stacked with GHRPs.

Human safety basis: No controlled human safety data

Key limitations: No established human dosage.; No controlled human trial results in the reviewed sources.; Not approved by the FDA for any use..

## Regulatory status

CJC-1295 (no DAC) / Mod GRF(1-29) is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

- FDA status: Not Approved
- WADA status: Banned in Sport
- Availability: Research-Only

## Frequently asked questions

### What is CJC-1295 (no DAC) / Mod GRF(1-29)?

Modified GRF(1-29), a growth hormone-releasing hormone analog carrying four amino-acid substitutions that resist enzymatic breakdown but without the drug affinity complex group that makes the DAC version long-acting. It is short-acting — its half-life is commonly estimated at about thirty minutes, although no published human study has measured it — rather than producing the multi-day elevation of DAC-CJC, and the two are pharmacologically distinct despite the shared name. Not FDA-approved. Prohibited in sport under WADA class S2.

### How does CJC-1295 (no DAC) / Mod GRF(1-29) work?

This is modified GRF(1-29), a GHRH analog carrying four amino-acid substitutions that protect it from dipeptidyl peptidase-4 cleavage but without the drug affinity complex group that lets the DAC version bind albumin. It binds the pituitary GHRH receptor, raising cyclic AMP and stimulating growth hormone release, but its half-life remains short — commonly estimated at about thirty minutes rather than days, although no published human pharmacokinetic study has measured it.

### Is CJC-1295 (no DAC) / Mod GRF(1-29) FDA approved?

No. CJC-1295 (no DAC) / Mod GRF(1-29) is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.

### What is the half-life of CJC-1295 (no DAC) / Mod GRF(1-29)?

No published human pharmacokinetic study has measured the half-life of CJC-1295 without DAC. It is commonly estimated at about 30 minutes, compared with 5.8–8.1 days measured for the DAC form (Teichman et al., 2006). Half-life describes how long the compound persists in circulation, not how long any effect lasts.

### Is CJC-1295 (no DAC) / Mod GRF(1-29) banned in sport?

CJC-1295 (no DAC) / Mod GRF(1-29) is recorded here as prohibited in sport. Athletes subject to anti-doping rules should check the current WADA Prohibited List directly, since it is revised annually and classifications change.

### What peptides are similar to CJC-1295 (no DAC) / Mod GRF(1-29)?

Compounds most often compared with CJC-1295 (no DAC) / Mod GRF(1-29) include Sermorelin, Tesamorelin, CJC-1295 and CJC-1295 (no DAC) + Ipamorelin. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [WADA Prohibited List 2026](https://www.wada-ama.org/en/prohibited-list)
- [Class-level evidence — Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults — J Clin Endocrinol Metab, 2006](https://pubmed.ncbi.nlm.nih.gov/16352683/)
- [Class-level evidence — Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions — J Am Acad Orthop Surg Glob Res Rev, 2026](https://pubmed.ncbi.nlm.nih.gov/41490200/)
- [Class-level evidence — Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians — Am J Sports Med, 2026](https://pubmed.ncbi.nlm.nih.gov/41476424/)
- [Class-level evidence — Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance — Sports Med, 2026](https://pubmed.ncbi.nlm.nih.gov/41966639/)
